ZYBERNO
Stock Report
Updated Aug 29, 2026

AXSOME THERAPEUTICS, INC. (AXSM)

Healthcare • NASDAQ

$200.79
Axsome Therapeutics Inc. is an American biopharmaceutical company headquartered in New York City that develops novel therapies for central nervous system (CNS) disorders. The company's marketed products include Auvelity (dextromethorphan-bupropion) for major depressive disorder, the first new mechanism approved for depression in decades, and Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy and sleep apnea.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
AXSOME THERAPEUTICS, INC. (AXSM) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-255.6%)
Debt-to-Equity (Solvency Risk):POOR (1.88x)
Operating Margin (Operational Efficiency):CRITICAL (-24.0%)
Return on Capital (Capital Efficiency):CRITICAL (-31.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

AXSOME THERAPEUTICS, INC. (AXSM) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, AXSM generated -$70.99M in Owner Earnings. Capital was deployed as follows: $263.00K invested in capital expenditures. Reinvestment rate: 4.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:200.79
Market Cap:$10.40B

Valuation Multiples (3)

P/B Ratio:124.85x
P/S Ratio:13.39x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$10.27B

Price Action & Momentum (3)

Momentum Percentile:94 / 100
% of 52-Week High:77.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-27.0%
Reinvestment Rate:4.2%
Fundamental Growth Rate (g):-1.3%

Margin Analysis (3)

Operating Margin Ttm:-24.0%
Net Margin Ttm:-24.7%
Ebitda Margin:-22.5%

TTM Performance (2)

Operating Margin Ttm:-24.0%
Net Margin Ttm:-24.7%

Yield Metrics (2)

Earnings Yield:-$1.86
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-8.3%
Latest Earnings Filed:2026-08-10

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):89.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.43x
Quick Ratio:1.34x
Cash Ratio:0.69x

Leverage Analysis (3)

Debt To Equity Ttm:1.88x
Debt-to-Equity Ratio:1.88x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:196,123,000.00
Cash And Cash Equivalents:319,850,000.00
Long Term Debt:$117.96M
Net Debt:-$131.89M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $776.57M
Linear Growth: 89.3%
📊 Click to view full AXSM Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$186.07M

Bottom Line Performance (3)

-$191.64M
Income Before Tax:-$191.09M
Ebitda Ttm:-174,456,000.00

Operating Expenses (5)

Operating Expenses:962,638,000.00
R And D Expense:187,857,000.00
Sga Expense:712,665,000.00
Income Tax Expense:-$402.00K
Interest Expense:-6,692,000.00

Expense Ratios (3)

R And D To Revenue Percentage:86.0%
Sga To Revenue Percentage:326.3%
Ebitda Margin:-22.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$761.45M
Current Assets:$656.57M
Ppe Net:874,000.00
Goodwill:12,042,000.00
Intangible Assets:$37.36M

Liability Structure (4)

Total Liabilities:678,143,000.00
Current Liabilities:460,446,000.00
Long Term Debt:$117.96M
Short Term Debt:$70.00M

Equity & Capital (3)

Equity:$83.30M
Retained Earnings:-$1.42B
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:277,459,000.00
Inventory:37,883,000.00
Accounts Payable:78,969,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:27,148,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$70.73M-$70.99M

Investment Activities (2)

Investing Cash Flow:-$121.00K
Capital Expenditures Ttm:263,000.00

Financing Activities (3)

Financing Cash Flow:$2.99M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:6,343,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$70.00M

Non-Cash Items (1)

Depreciation Amortization Ttm:11,613,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.74
-$3.74
Earnings Per Share Ttm:-$3.70

Revenue & Cash Per Share (2)

Sales Per Share Ttm:14.99
Operating Cash Flow Per Share:-$1.80

Book Value & Capital (2)

Book Value Per Share:$1.61
Cash Per Share:6.17

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.10x
Working Capital Turnover Ttm:3.96x

Receivables Management (2)

Receivables Turnover Ttm:2.80x
Days Sales Outstanding Ttm:130.41

Inventory Management (2)

Inventory Turnover Ttm:20.50x
Days Inventory Outstanding Ttm:17.81

Payables & Cash Cycle (2)

Days Payable Outstanding:37.12
Cash Conversion Cycle:111.10
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$70.99M

Damodaran Growth Analysis (2)

Reinvestment Rate:4.2%
Fundamental Growth Rate (g):-1.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):89.3%

Other Growth Rates (1)

Book Value Growth Rate (Linear):8.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:AXSM
Company Name:AXSOME THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:premium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:51.80M
Shares Outstanding Basic:51.80M
Shares Outstanding Diluted:51.80M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 09:25:46 UTC
Data Timestamp:2026-08-29T09:25:46.098970
Scroll to Top